FDA clears testing for another gene-editing drug in humans

The FDA has signed off on a Massachusetts startup's plans to launch its first-ever clinical trial, which will make it among the first U.S. companies to test the gene editing technology CRISPR/Cas9 in humans. Cambridge-based Editas Medicine (Nasdaq: EDIT) said Friday, Nov. 30, that the FDA had approved the launch of an early-stage trial of its drug for the most common cause of childhood blindness. The treatment uses CRISPR/Cas9, which allows scientists to replace or eliminate disease-causing segments…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news